

DATA REPORT

Open Access

Prevalence of pharmacogenomic variants in 100 pharmacogenes among Southeast Asian populations under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm)

Chakkaphan Runcharoen¹, Koya Fukunaga², Insee Sorn¹, Nareenart Iemwimangsa¹, Sommon Klumsathian¹, Hang Tong³, Nam Sy Vo⁴, Ly Le^{3,4}, Tin Maung Hlaing⁵, Myo Thant⁶, Shamsul Mohd Zain⁷, Zahurin Mohamed⁷, Yuh-Fen Pung⁸, Francis Capule⁹, Jose Nevado Jr.¹⁰, Catherine Lynn Silao^{10,11}, Zeina N. Al-Mahayri¹², Bassam R. Ali¹³, Rika Yuliwulandari^{14,15}, Kinasih Prayuni¹⁵, Hilyatuz Zahroh¹⁵, Dzul Azri Mohamed Noor¹⁶, Phonepadith Xangsayarath¹⁷, Dalouny Xayavong¹⁷, Sengchanh Kounnavong¹⁸, Somphou Sayasone¹⁸, Zoe Kordou¹⁹, Ioannis Liopetas¹⁹, Athina Tsikrika¹⁹, Evangelia-Eirini Tsermpini¹⁹, Maria Koromina¹⁹, Christina Mitropoulou²⁰, George P. Patrinos^{12,19}, Aumpika Kesornsit²¹, Angkana Charoenyngwattana¹, Sukanya Wattanapokayakit²², Surakameth Mahasirimongkol²², Taisei Mushiroda² and Wasun Chantratita¹

Abstract

Pharmacogenomics can enhance the outcome of treatment by adopting pharmacogenomic testing to maximize drug efficacy and lower the risk of serious adverse events. Next-generation sequencing (NGS) is a cost-effective technology for genotyping several pharmacogenomic loci at once, thereby increasing publicly available data. A panel of 100 pharmacogenes among Southeast Asian (SEA) populations was resequenced using the NGS platform under the collaboration of the Southeast Asian Pharmacogenomics Research Network (SEAPharm). Here, we present the frequencies of pharmacogenomic variants and the comparison of these pharmacogenomic variants among different SEA populations and other populations used as controls. We investigated the different types of pharmacogenomic variants, especially those that may have a functional impact. Our results provide substantial genetic variations at 100 pharmacogenomic loci among SEA populations that may contribute to interpopulation variability in drug response phenotypes. Correspondingly, this study provides basic information for further pharmacogenomic investigations in SEA populations.

Pharmacogenomics is the study of how an individual's genomic profile influences their response to drug treatments. This has emerged as a potential tool to optimize medications and reduce adverse drug events¹. Genotyping data from next-generation sequencing (NGS) technologies are increasing in international public databases, thereby enabling new advances in pharmacogenomic research. Implementation guidelines of the data are now

Correspondence: Taisei Mushiroda (mushiroda@riken.jp) or Wasun Chantratita (wasun.cha@mahidol.ac.th)

¹Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

²Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

Full list of author information is available at the end of the article

These authors contributed equally: Chakkaphan Runcharoen, Koya Fukunaga

© The Author(s) 2021



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC)².

The Southeast Asian Pharmacogenomics Research Network (SEAPharm) was founded in 2012. SEAPharm aims to be the regional pharmacogenomics (PGx) network to strengthen the knowledge of PGx research and its implementation approaches in SEA countries³. In 2018, the annual SEAPharm meeting approved an expanded research collaboration under the project entitled “Re-sequencing Project of 1,000 Southeast Asian Individuals Using the 100 Pharmacogene - Next Generation Sequencing Panel” using the NGS platform. Nine countries participated in this project: seven countries from Southeast Asia (Indonesia, Laos, Malaysia, Myanmar, Philippines, Thailand, and Vietnam) and one each from Europe (Greece) and Western Asia (United Arab Emirates; UAE).

The 100 PKSeq panel is composed of 37 drug transporter genes, 30 cytochrome P450 (CYP) enzyme-encoded genes, 10 uridine diphosphate glucuronosyltransferase (UGT) genes, 5 flavin-containing monooxygenase (FMO) genes, 4 glutathione S-transferase (GST) genes, 4 sulfotransferase (SULT) genes, and others⁴. Initially, the 100 pharmacogene resequencing processes were performed by RIKEN, Japan. Genomic DNA samples were collected from nine countries: Indonesia ($N = 562$), Laos ($N = 100$), Malaysia ($N = 105$), Myanmar ($N = 100$), the Philippines ($N = 100$), Thailand ($N = 100$), Vietnam ($N = 100$), the UAE ($N = 100$), and Greece ($N = 304$). The latter two populations were used as a control for the former seven populations. Targeted resequencing processes were performed as described previously⁴. After sequencing, the raw data (.fastq files) were further analyzed by the Center for Medical Genomics, Thailand, for primary sequence analysis. Sequencing reads were aligned to the human reference genome (GRCh37/hg19) by using the Burrows-Wheeler Aligner (0.7.17). Variants, including single-nucleotide polymorphisms (SNPs) and short insertions and deletions (indels), were called using the Genome Analysis Toolkit (GATK, v3.5)⁵. Variant quality score recalibration (VQSR) was also applied as call set refinement to reduce the number of false-positive calls. BCFtools was used to manipulate the variant calling format (.vcf) files and to calculate the pairwise weighted F_{st} value. Linkage disequilibrium (LD) plots were created by LDBlockShow (Supplementary Figs. 1–13)⁶. Downstream variant annotation and statistical analysis, including plotting, were performed using VarSeq (Golden Helix, Inc., Bozeman, MT, USA, www.goldenhelix.com.) and R software (R Foundation for Statistical Computing, Vienna, Austria, www.R-project.org).

In this report, the frequencies of pharmacogenomic variants in SEA populations based on the 100 PKSeq panel are reported (Supplementary Tables 1–7). Based on

the variant calling processes, 3527 variants were called and passed for VQSR processes. In total, 306 variants (excluding multiallelic variants) were jointly observed in the SEA populations (Supplementary Table 8). To quantify the differences in frequencies between this dataset and the public genome dataset, the frequencies of the 306 variants identified in this dataset and in the East Asian (EAS) control datasets from the Genome Aggregation Database (gnomAD v.2.1.1) were compared using scatter plots and correlation coefficient analysis (Fig. 1a). The results revealed concordance between the allelic frequencies in this dataset (in all the SEA populations) and in the EAS dataset from gnomAD. Considering the correlation coefficient R , there was a trend of high correlations in the frequencies of variants in the Thailand, Vietnam, and EAS datasets. To investigate the proportion of the total pharmacogenomic variants contained in SEA populations, pairwise F_{st} statistics of the seven SEA countries, UAE, and Greece were performed. The results indicated that the SEA populations had modest genetic similarity (pairwise F_{st} value <0.05 ; Fig. 1b). The greatest genetic similarity was observed in the mainland SEA populations based on their pharmacogenomic background. The Malaysian population seemed to share more similarities with other SEA populations, with the Philippines showing the least similarities among the SEA neighbors. To our knowledge, this is the first report to compare the total pharmacogenomic variants between SEA populations based on the 100 PKSeq panel. A previous study demonstrated the comparison of pairwise F_{st} values between Singapore Genome Variation Project (SGVP) populations (Chinese (CHS), Indian (INS), and Malay (MAS)), South Asians (SAS), and Europeans by using the variants of ADME⁷. The results showed that the CHS and MAS populations were profoundly different from the SAS and INS populations, which exhibited substantial similarity⁷.

The allele frequencies of the genes responsible for drug metabolism enzymes and transporters in the SEA populations were then explored^{8,9}. The frequencies of the variants of *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A4*, *ABCB1*, *ABCG2*, *SLC22A2*, *SLC22A6*, *SLC22A8*, *SLCO1B3*, and *SLCO1B3*, which were jointly observed in the SEA populations, are shown in Fig. 2a. Two variants of *CYP2D6* differed in the observed minor allele frequencies (MAFs), with an allele frequency <0.5 , between the SEA populations. The MAF of *CYP2D6* rs1065852 (A) was 0.410 in and 0.495 in the Burmese and Malaysian populations. The frequency of the A allele of *CYP2D6* rs1081003 was 0.395, 0.490, and 0.492 in the Burmese, Malaysian, and Indonesian populations; however, allele A was found to be a major allele in other SEA populations. As previously described, the frequencies of pharmacogenomic variants among the sample population from





Fig. 1 Scatter plot and correlation coefficient of this dataset and EAS datasets from gnomAD and pairwise weighted F_{st} statistics between SEA populations. **a** Frequencies of the 306 pharmacogenomic variants between this dataset and East Asian (EAS) datasets from gnomAD. AF Allele frequency. **b** Pairwise weighted F_{st} statistics between SEA, UAE, and Greek populations.

Myanmar residing in the USA demonstrated that the MAF of rs1065852 was higher in this population (A) (MAF = 0.36) than in the American (AMR, MAF = 0.15) and South Asian (SAS, MAF = 0.16) populations and slightly lower than that in the EAS population¹⁰. rs1065852 (A) is recognized as a key mutation in *CYP2D6*10*. In Malaysia, the allelic frequencies of *CYP2D6*10* differed between the Chinese-Malaysians, Malay-Malaysians, and Indian-Malaysians¹¹. Only the MAF of the *CYP2D6*10* allele was noted in the Indian-Malaysians (MAF = 0.214). However, the frequencies of rs1065852 (A) are not represented for *CYP2D6* copy number variation (CNV)-variable haplotypes such as *CYP2D6*36*. The frequency of rs1081003 (A) was 0.412 among the Chinese population. The frequencies also

varied among subpopulations (i.e., Shanghai (MAF = 0.484), Xi'an (MAF = 0.407), Shenyang (MAF = 0.467), and Shantou (MAF = 0.288))¹². In addition, this variant has been reported as a major allele in Taiwanese¹³. The LD plot of *CYP2D6* in the population revealed that five SNPs (rs1135840, rs16947, rs1058164, rs1081003, and rs1065852) in the Philippinean, Thailand, and Vietnamese populations and three SNPs (rs1058164, rs1081003, and rs1065852) in the Laos population were in very high LD (Supplementary Fig. 13). These SNPs are key mutations in *CYP2D6*10A* and *CYP2D6*54* and cause a decrease in enzyme activity. As previously described, *CYP2D6*10* is responsible for the intermediate metabolizer status in SEA populations. However, the prevalence of these alleles is low in Malay-Singaporeans, Chinese-Singaporeans,



Indian-Malaysians, and Indian-Singaporeans¹⁴. Additionally, two variants of the drug transporter genes, namely, rs1128503 (G) and rs2291075 (T) of *ABCB1* and *SLCO1B1*, respectively, differed in the observed allele frequencies between populations (Fig. 2b). Interestingly, some *ABCB1* variants seem to be more frequent in Filipinos, such as rs1045642 (G), with an allele frequency of 0.71. However, *ABCB1* rs1128503 (G), a minor allele in other SEA populations, was found to be a major allele among Filipinos. Previously, rs1128503 (G) was documented as a major allele among Chinese and Singaporean populations; however, rs1128503 (G) was found to be a minor allele in the Indonesian population^{15,16}. rs1128503, rs2032582, and rs1045642 are the most common SNPs in the coding region of *ABCB1*; moreover, these SNPs are in strong LD¹⁷. The homozygous variants for one of three *ABCB1* variants, rs1128503 (T), rs2032582 (T, A), and rs1045642 (T), are associated with significantly high short-term remission rates after tacrolimus treatment in steroid-refractory ulcerative colitis (UC) patients¹⁸. The

MAFs of rs2291075 (T) are 0.400 and 0.470 in the Burmese and Vietnamese populations. In Singapore, the frequencies of rs2291075 (T) vary between subpopulations (CHS, INS, and MAS); nonetheless, the MAF was observed only in INS (MAF = 0.031)¹⁹. Moreover, rs2291075 (T) was previously described as a MAF in Korean (MAF = 0.436) and Japanese (MAF = 0.367) populations. In contrast, this variant was found to be a major allele among the Chinese population²⁰. rs2291075, which encodes the transporter OATP1B1, is in strong LD with rs2306283 and rs4149056. Inheritance of variability in the transporter OATP1B1 may influence the effectiveness of acute myeloid leukemia (AML) therapy because this transporter is responsible for the systemic pharmacokinetics of several drugs used in AML treatment²¹.

Although the SEA populations seem to have genetic similarities, differences in allele frequencies between the populations were observed. A previous large-scale study of pharmacogenomic biomarkers in 18 European populations demonstrated allele frequency differences in the interpopulations²². Additionally, the genotyping of CYP genes across Native American and Ibero-American populations revealed differences within Native Americans²³. These findings support that ethnicity affects differences in drug response and/or toxicity. To support the need for personalized precision medicine, the interethnic differences of SEA populations should be taken into consideration to reliably predict drug safety and efficacy at the population level.

We further investigated the functional impact of these pharmacogenomic variants, including deleterious missense mutations and loss-of-function mutations, among the SEA populations. Deleterious missense mutations were determined by multiple algorithms from a database for the functional predictions of nonsynonymous SNPs (dbNSFP v3.0) via VarSeq (Golden Helix, Inc., Bozeman, MT, USA, www.goldenhelix.com). Considering the functional impacts of the variants (i.e., major allele frequencies and MAFs), there was a trend of higher proportions of deleterious missense and loss-of-function mutations in the MAF variants (Supplementary Fig. 14). In particular, rare variants (MAF < 0.01) accounted for the highest proportions of deleterious missense and loss-of-function mutations. Whole-genome sequencing of Malaysians revealed 693 variants of 8550 predicted deleterious variants in 437 pharmacogenomic genes involved in drug metabolism. Almost seventy percent (70%) of the variants were rare alleles²⁴. The investigation of variants in 12 CYP genes revealed that the majority of variants are remarkably rare in both African-American and European-American ancestries²⁵. Additionally, a large proportion of rare alleles with the potential to impact drug metabolism has been documented in Slovenian and Latino

populations^{26,27}. This is also supported by the investigation of individual variants by sequencing drug target genes, which demonstrated that rare variants are abundant in humans, and many have potentially relevant effects on drug metabolism^{25,28,29}. Rare variants of pharmacogenes are significantly associated with variations that contribute to a significant portion of the unexplained interindividual differences in drug metabolism phenotypes, thereby causing functional alterations^{28,30}.

In conclusion, this report presents the data on the frequencies of 100 pharmacogenes from the 100 PKSeq resequencing panel. We reported the frequencies of the pharmacogenomic variants and compared the pharmacogenomic variants among different SEA populations. Additionally, we examined the functional impact of the pharmacogenomic variants that potentially caused functional alterations. These data provide a useful resource for future pharmacogenomic research in SEA populations.

Acknowledgements

We appreciate all participants not listed as coauthors. This study was supported by the Thailand Center of Excellence for Life Sciences (TCELS), the International Research Network (IRN60W0003), and the Thailand Research Fund (TRF). B.R.A. and Z.N.A. would like to thank UAEU and the Ministry of Education for funding (31R091).

Author details

¹Center for Medical Genomics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. ²Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ³School of Biotechnology, International University, Vietnam National University, Ho Chi Minh City, Vietnam. ⁴Vingroup Big Data Institute, Hanoi, Vietnam. ⁵Defence Services Medical Academy, Mingalardon, Myanmar. ⁶Defence Services Medical Research Centre, Nay Pyi Taw, Myanmar. ⁷Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. ⁸Department of Biomedical Sciences, University of Nottingham (Malaysia Campus), Selangor, Malaysia. ⁹Department of Pharmacy, College of Pharmacy, University of the Philippines Manila, Manila, Philippines. ¹⁰Institute of Human Genetics, National Institutes of Health, University of the Philippines Manila, Manila, Philippines. ¹¹Department of Pediatrics, Philippine General Hospital and College of Medicine, University of the Philippines Manila, Manila, Philippines. ¹²Department of Pathology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. ¹³Department of Pathology and Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. ¹⁴Department of Pharmacology, Faculty of Medicine, YARSI University, Jakarta, Indonesia. ¹⁵Genetic Research Center, YARSI Research Institute, YARSI University, Jakarta, Indonesia. ¹⁶School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia. ¹⁷National Center for Laboratory and Epidemiology (NCLE), Vientiane, Lao PDR. ¹⁸Lao Tropical and Public Health Institute, Vientiane, Lao PDR. ¹⁹University of Patras, School of Health Sciences, Department of Pharmacy, Laboratory of Pharmacogenomics and Individualised Therapy, Patras, Greece. ²⁰The Golden Helix Foundation, London, UK. ²¹Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand. ²²Division of Genomic Medicine and Innovation Support, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand

Conflict of interest

The authors declare that they have no conflicts of interest. GPP is a Full Member and a National Representative of the European Medicines Agency, CHMP-Pharmacogenomics Working Party, Amsterdam, the Netherlands.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41439-021-00135-z>.

Received: 24 July 2020 Revised: 24 November 2020 Accepted: 28 November 2020.

Published online: 4 February 2021

References

- Hockings, J. K. et al. Pharmacogenomics: an evolving clinical tool for precision medicine. *Cleve Clin. J. Med.* **87**, 91–99 (2020).
- Hippman, C. & Nislow, C. Pharmacogenomic testing: clinical evidence and implementation challenges. *J. Pers. Med.* **9**, 40 (2019).
- Chumnumwat, S. et al. Southeast asian pharmacogenomics research network (SEAPharm): current status and perspectives. *Public Health Genomics* **22**, 132–139 (2019).
- Yoshihama, T. et al. GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes. *Oncotarget* **9**, 29789–29800 (2018).
- McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* **20**, 1297–1303 (2010).
- Dong, S.-S. et al. LDBlockShow: a fast and convenient tool for visualizing linkage disequilibrium and haplotype blocks based on variant call format files. *bioRxiv*. <https://doi.org/10.1093/bib/bbaa227> (2020).
- Chan, S. L. et al. Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. *Pharmacogenet. Genom.* **26**, 28–39 (2016).
- Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. *Trends Pharmacol. Sci.* **25**, 193–200 (2004).
- Nigam, S. K. What do drug transporters really do? *Nat. Rev. Drug Discov.* **14**, 29–44 (2015).
- Hoefler, C. C. et al. Allelic frequencies of 60 pharmacogene variants assessed within a Burmese population residing in northeast Indiana, USA. *Pharmacogenomics* **19**, 393–399 (2018).
- Chin, F. W., Chan, S. C., Abdul Rahman, S., Noor Akmal, S. & Rosli, R. CYP2D6 genetic polymorphisms and phenotypes in different ethnicities of Malaysian breast cancer patients. *Breast J.* **22**, 54–62 (2016).
- Qin, S. et al. Systematic polymorphism analysis of the CYP2D6 gene in four different geographical Han populations in mainland China. *Genomics* **92**, 152–158 (2008).
- Lu, H. C., Chang, Y. S., Chang, C. C., Lin, C. H. & Chang, J. G. Developing and evaluating the HRM technique for identifying cytochrome P450 2D6 polymorphisms. *J. Clin. Lab Anal.* **29**, 220–225 (2015).
- Dorji, P. W., Tshering, G. & Na-Bangchang, K. CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South-East and East Asian populations: a systematic review. *J. Clin. Pharm. Ther.* **44**, 508–524 (2019).
- Ahmed, S. S., Husain, R. S., Kumar, S. & Ramakrishnan, V. Association between MDR1 gene polymorphisms and Parkinson's disease in Asian and Caucasian populations: a meta-analysis. *J. Neurol. Sci.* **368**, 255–262 (2016).
- Rinaldi, I. et al. Association between C1236T genetic variant of ABCB1 gene and molecular response to imatinib in Indonesian chronic myeloid patients. *Asian Pac. J. Cancer Prev.* **20**, 3331–3334 (2019).
- Wang, D., Johnson, A. D., Papp, A. C., Kroetz, D. L. & Sadee, W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. *Pharmacogenet. Genom.* **15**, 693–704 (2005).
- Herrlinger, K. R. et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. *Clin. Pharmacol. Ther.* **89**, 422–428 (2011).
- Ho, W. F., Koo, S. H., Yee, J. Y. & Lee, E. J. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. *Drug Metab. Pharmacokin.* **23**, 476–482 (2008).
- Namgoong, S. et al. Comparison of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes among five ethnic groups. *Environ. Toxicol. Pharmacol.* **40**, 692–697 (2015).

21. Drenberg, C. D. et al. Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. *Clin. Pharmacol. Ther.* **99**, 651–660 (2016).
22. Mizzi, C. et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. *PLoS ONE* **11**, e0162866 (2016).
23. Naranjo, M. G. et al. Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. *OMICS* **22**, 575–588 (2018).
24. Sivadas, A., Salleh, M. Z., Teh, L. K. & Scaria, V. Genetic epidemiology of pharmacogenetic variants in South East Asian Malays using whole-genome sequences. *Pharmacogenomics J.* **17**, 461–470 (2017).
25. Gordon, A. S. et al. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. *Hum. Mol. Genet.* **23**, 1957–1963 (2014).
26. Gonzalez-Covarrubias, V. et al. Variation in actionable pharmacogenetic markers in natives and mestizos From Mexico. *Front. Pharmacol.* **10**, 1169 (2019).
27. Hocevar, K., Maver, A. & Peterlin, B. Actionable pharmacogenetic variation in the slovenian genomic database. *Front Pharmacol.* **10**, 240 (2019).
28. Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. *Genet. Med.* **19**, 20–29 (2017).
29. Wright, G. E. B., Carleton, B., Hayden, M. R. & Ross, C. J. D. The global spectrum of protein-coding pharmacogenomic diversity. *Pharmacogenomics J.* **18**, 187–195 (2018).
30. Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y. & Lauschke, V. M. Integrating rare genetic variants into pharmacogenetic drug response predictions. *Hum. Genom.* **12**, 26 (2018).